Frazier Financial Advisors’s Aurinia Pharmaceuticals AUPH Stock Holding History

Frazier Financial Advisors’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.48K	Sell	500 -2,971	-86%	-$47.5K	﹤0.01%	427
2026 Q1	$51.4K	Buy	3,471 +2,793	+412%	+$40.8K	0.03%	181
2025 Q4	$10.8K	Buy	678 +178	+36%	+$2.52K	0.01%	347
2025 Q3	$5.53K	Sell	500 -500	-50%	-$5.46K	﹤0.01%	443
2025 Q2	$8.47K	Buy	1,000 +500	+100%	+$4.01K	0.01%	378
2025 Q1	$4.02K	Hold	500	–	–	﹤0.01%	462
2024 Q4	$4.58K	Sell	500 -2,984	-86%	-$24.3K	﹤0.01%	455
2024 Q3	$25.5K	Sell	3,484 -1,613	-32%	-$10K	0.02%	228
2024 Q2	$29.1K	Buy	5,097 +4,597	+919%	+$24.2K	0.02%	223
2024 Q1	$2.5K	Hold	500	–	–	﹤0.01%	729
2023 Q4	$4.5K	Buy	+500	New	+$4.12K	﹤0.01%	521

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Frazier Financial Advisors's AUPH Position: Q2 2026 in Review

Frazier Financial Advisors reduced its Aurinia Pharmaceuticals (AUPH) stake by 86% in Q2 2026, selling an estimated $47.5K and leaving 500 shares worth $8.48K. The position accounts for ﹤0.01% of the portfolio, ranked #427.

Frazier Financial Advisors first reported a position in AUPH in Q4 2023 and has held it in 11 quarters since. The position peaked at $51.4K in Q1 2026. 283 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

Frazier Financial Advisors held 500 shares of Aurinia Pharmaceuticals worth $8.48K as of Q2 2026.
Frazier Financial Advisors sold 2,971 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $47.5K.
Aurinia Pharmaceuticals made up ﹤0.01% of Frazier Financial Advisors's portfolio in Q2 2026, its #427 holding.
Frazier Financial Advisors first reported a position in Aurinia Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
Frazier Financial Advisors's Aurinia Pharmaceuticals position peaked at $51.4K in Q1 2026.
283 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Frazier Financial Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.